TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1776351

Group type: EXPERIMENTAL
Intervention: Aqueous CO2 (succinate + sodium bicarbonate = Kao Bub; 1400 mg CO2 per kg water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fresh water
Number of subjects: 15
Study: 7295467

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study: 31899024

Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (TXA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Topical Oxymetazoline
Number of subjects: 38
Study: 30732134

Group type: EXPERIMENTAL
Intervention: Tobramycin/dexamethasone eye drops
Number of subjects: 409

Group type: COMPARATOR
Intervention: Tobramycin/dexamethasone ointment
Number of subjects: 409

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 409
Study: 29880851

Group type: EXPERIMENTAL
Intervention: Randomized placement into a family caregiving environment during the infant/toddler period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged institutional care
Number of subjects: 0
Study: 25759418

Group type: EXPERIMENTAL
Intervention: Lidocaine 10% spray
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 200
Study: 23887339

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 294
Study: 22835779

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced total body CT scan (head to pelvis) during the primary survey
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional trauma imaging protocols supplemented with selective CT scanning
Number of subjects: 0
Study: 19559353

Group type: EXPERIMENTAL
Intervention: Lymphotropic nanoparticle enhanced MRI (LNMRI) using superparamagnetic nanoparticle ferumoxtran-10
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lymphotropic nanoparticle enhanced MRI (LNMRI)
Number of subjects: 26
Study: 18162137

Group type: EXPERIMENTAL
Intervention: 500 mcg fluticasone propionate twice daily
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 15817593

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF chemotherapy (early, delayed, or both)
Number of subjects: 2881

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 2881
Study: 12418594

Group type: EXPERIMENTAL
Intervention: 5 days of oral prednisolone (40 mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10626612

Group type: EXPERIMENTAL
Intervention: Peer-based intervention including principles derived from the health belief model
Number of subjects: 244

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 244
Study: 7560625

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing with a 100-ms AV delay
Number of subjects: 12

Group type: COMPARATOR
Intervention: Backup mode (VVI at 40 beats/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (VDD mode)
Number of subjects: 12
Study: 2137901

Group type: EXPERIMENTAL
Intervention: 6 g per day of 85 percent eicosapentaenoic and docosahexaenoic acids
Number of subjects: 156

Group type: COMPARATOR
Intervention: 6 g per day of corn oil
Number of subjects: 156

Group type: COMPARATOR
Intervention: Comparison between fish oil and corn oil
Number of subjects: 156
Study: 512005

Group type: EXPERIMENTAL
Intervention: Exaggerated attending to manifestations of anxiety
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exaggerated relevant anxiety response
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exaggerated irrelevant anxiety response
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Imagined exaggerated consequence of anxiety
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study: 31039070

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control
Number of subjects: 720
Study: 30414782

Group type: EXPERIMENTAL
Intervention: 4CMenB/MenACWY
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 750

Group type: COMPARATOR
Intervention: MenACWY
Number of subjects: 750
Study: 26402722

Group type: EXPERIMENTAL
Intervention: Information and personal contact with individuals with CLP
Number of subjects: 189

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 189
Study: 24994571

Group type: EXPERIMENTAL
Intervention: SVV-based goal-directed therapy (GDT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard fluid management (control)
Number of subjects: 80
Study: 20491816

Group type: EXPERIMENTAL
Intervention: Synthetic biphasic calcium phosphate (BCP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both BCP and DBB
Number of subjects: 11
Study: 20837684

Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen every two weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Topical salicylic acid self-application daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait-and-see approach
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen every two weeks (for common warts)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Topical salicylic acid self-application daily (for common warts)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait-and-see approach (for common warts)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cryotherapy, topical salicylic acid, wait-and-see (for plantar warts)
Number of subjects: 240
Study: 18579806

Group type: EXPERIMENTAL
Intervention: l-dopa/decarboxylase inhibitor (DDCI)
Number of subjects: 782

Group type: COMPARATOR
Intervention: bromocriptine
Number of subjects: 782

Group type: COMPARATOR
Intervention: l-dopa/DDCI plus selegiline
Number of subjects: 782
Study: 16150199

Group type: EXPERIMENTAL
Intervention: Shugan Shuru Granule (SSG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 66
Study: 12390953

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/d, titrated to 20 mg/d and then 40 mg/d)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 10197493

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) followed by one or two sessions of sclerotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy with 5% ethanolamine oleate
Number of subjects: 50
Study: 7776775

Group type: EXPERIMENTAL
Intervention: 28 g alpha‐ketoglutarate added to blood cardioplegia for intermittent antegrade intracoronary perfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no alpha‐ketoglutarate)
Number of subjects: 24
Study: 2178428

Group type: EXPERIMENTAL
Intervention: Doppler flow velocity waveform analysis at 24 weeks' gestation
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Umbilical artery systolic to diastolic ratios at 24, 28, and 34 weeks' gestation
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Doppler systolic to diastolic ratios
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Doppler systolic to diastolic ratios as primary screening tests
Number of subjects: 535
Study: 7234455

Group type: EXPERIMENTAL
Intervention: Luteal phase of the menstrual cycle
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: D-Norgestrel (2.5 mg/die)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Estradiolvalerate (5 mg/die)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mesterolone (100 mg/die)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31574796

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cleaning of the tongue with a tongue scraper
Number of subjects: 40
Study: 28633147

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 2 doses of 15 mg/kg intravenous TXA dissolved in 100 mL of saline, administered over 10 minutes; 1 dose before incision, 1 dose at wound closure.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo - 100 mL of saline solution administered in a similar fashion to TXA.
Number of subjects: 138
Study: 25298165

Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg once daily and metformin (uptitrated to 2000mg/day maximum)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Linagliptin monotherapy
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Linagliptin and metformin combination therapy
Number of subjects: 316
Study: 23541974

Group type: EXPERIMENTAL
Intervention: Rapid-rate nonsustained ventricular tachycardia (RR-NSVT)
Number of subjects: 811
Study: 21777700

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral anticoagulant (OAC)
Number of subjects: 0
Study: 19114612

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: COMPARATOR
Intervention: Metformin XR
Number of subjects: 5
Study: 16505738

Group type: EXPERIMENTAL
Intervention: Information, education, and communication (IEC) interventions; condom social marketing (CSM); voluntary counseling and testing (VCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public and private sexually transmitted infections treatment
Number of subjects: 0
Study: 15311441

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study: 11028725

Group type: EXPERIMENTAL
Intervention: General anaesthesia with thoracic epidural analgesia (TEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 30
Study: 9296318

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg, twice daily for 5 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8068603

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 20
Study: 3057476

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 15
Study: 29396978

Group type: EXPERIMENTAL
Intervention: HIIT-2 (10×60‐s cycling at 83% of peak power, two times per week for eight weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HIIT-3 (10×60‐s cycling at 83% of peak power, three times per week for eight weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study: 26219670

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 210
Study: 23698074

Group type: EXPERIMENTAL
Intervention: Cystatin C (Gentian)
Number of subjects: 16279

Group type: EXPERIMENTAL
Intervention: Cystatin C (Roche)
Number of subjects: 16279

Group type: EXPERIMENTAL
Intervention: Combined creatinine-cystatin C equation (Gentian)
Number of subjects: 16279

Group type: EXPERIMENTAL
Intervention: Combined creatinine-cystatin C equation (Roche)
Number of subjects: 16279

Group type: EXPERIMENTAL
Intervention: CKD-EPI eGFR
Number of subjects: 16279
Study: 20673569

Group type: COMPARATOR
Intervention: Observation of stimulus (Obs-S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation of stimulus and action (Obs-SA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical practice (PP)
Number of subjects: 0
Study: 18355332

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 35
Study: 16963663

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (IV administration)
Number of subjects: 6219

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (subcutaneous administration)
Number of subjects: 6219

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 6219

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 6219
Study: 12792378

Group type: COMPARATOR
Intervention: cp‐45 vaccine (106 pfu in adults and seropositive children; 104 and 105 pfu in seronegative children; two doses of 104 pfu in infants at 1 or 3 month intervals)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: cp‐45 vaccine (two doses of 104 pfu in infants)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: cp‐45 vaccine
Number of subjects: 145
Study: 11089754

Group type: EXPERIMENTAL
Intervention: 4% succinylated modified fluid gelatin (MFG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 34
Study: 8682818

Group type: EXPERIMENTAL
Intervention: Above-knee graded compression stockings
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Below-knee graded compression stockings
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 177
Study: 1758941

Group type: EXPERIMENTAL
Intervention: Pre-event glucose ingestion (50 g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo ingestion (identically sweetened and colored)
Number of subjects: 13
Study: 6281704

Group type: EXPERIMENTAL
Intervention: Intravenous Premarin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31823549

Group type: EXPERIMENTAL
Intervention: 3D‐MIPO
Number of subjects: 120

Group type: COMPARATOR
Intervention: traditional MIPO
Number of subjects: 120
Study: 29037620

Group type: EXPERIMENTAL
Intervention: Strengthening exercises for wrist flexors and extensors (6 weeks, home exercises using a bucket filled with water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention, lifestyle as usual)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (training and control)
Number of subjects: 30
Study: 25779558

Group type: EXPERIMENTAL
Intervention: Lapatinib plus taxane therapy
Number of subjects: 652

Group type: COMPARATOR
Intervention: Trastuzumab plus taxane therapy
Number of subjects: 652
Study: 24494297

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided acupotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular acupotomy
Number of subjects: 80
Study: 20966402

Group type: EXPERIMENTAL
Intervention: Moderate or intensive statin therapy
Number of subjects: 3501
Study: 19407678

Group type: EXPERIMENTAL
Intervention: Five-night regimen of 25-microg vaginal estradiol tablet inserted nightly for five nights
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Single 25-microg vaginal estradiol tablet before the test
Number of subjects: 154

Group type: COMPARATOR
Intervention: No previous estrogen administration (control group)
Number of subjects: 154
Study: 17187405

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide (Sandostatin LAR 30 mg) intramuscularly every 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15112861

Group type: EXPERIMENTAL
Intervention: Multiple doses of losigamone (600 mg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11402636

Group type: EXPERIMENTAL
Intervention: Community pharmacy-based intervention including education on disease, pharmacotherapy, and self-management; inhalation technique assessment and correction.
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Community pharmacy-based intervention.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 161
Study: 9669459

Group type: EXPERIMENTAL
Intervention: X‐MS dragees (8 g X per day)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: X‐PD dragees (8 g X per day)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no saliva stimulants)
Number of subjects: 188
Study: 7716018

Group type: EXPERIMENTAL
Intervention: Water birth
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional birth
Number of subjects: 32
Study: 2658606

Group type: EXPERIMENTAL
Intervention: Weekly cervical examinations and instruction regarding subtle symptoms and signs of preterm labor
Number of subjects: 4595

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 4595

Group type: EXPERIMENTAL
Intervention: Year 1 (all patients received preterm birth precautions)
Number of subjects: 4595

Group type: EXPERIMENTAL
Intervention: Private study patients
Number of subjects: 4595
Study: 773391

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 36
Study: 31375503

Group type: EXPERIMENTAL
Intervention: Central monitor position (eye-level on the radiant warmer)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peripheral monitor position (above eye-level, wall-mounted)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Central monitor position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peripheral monitor position
Number of subjects: 30
Study: 31050986

Group type: EXPERIMENTAL
Intervention: Skin prick test with allergen extracts (Mixture of Weeds and Mixture of Grass)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Molecular investigations for allergen sensitization
Number of subjects: 126
Study: 28533290

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 800 mg/day
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study: 26120594

Group type: EXPERIMENTAL
Intervention: Spear and Shield intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study: 22795088

Group type: EXPERIMENTAL
Intervention: OCP compliant users (EE2 and LNG)
Number of subjects: 0
Study: 21163939

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 μg twice daily for 1 year
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 19625946

Group type: EXPERIMENTAL
Intervention: 0.7 mg/day rhGH for 40 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 16539642

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Rosiglitazone (Control)
Number of subjects: 23
Study: 12589449

Group type: EXPERIMENTAL
Intervention: Instructions in terms of fingers/hands for responding in visual and auditory Simon tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory stimuli with finger/hand instructions in Experiment 4
Number of subjects: 0
Study: 11097665

Group type: EXPERIMENTAL
Intervention: Epidural injection of 10 mL saline
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Epidural injection of 10 mL 0.25% bupivacaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: 8 mg of 0.5% hyperbaric bupivacaine intrathecally
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 66
Study: 9351153

Group type: EXPERIMENTAL
Intervention: Random allocation of treatment
Number of subjects: 0
Study: 8176999

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 71
Study: 2412071

Group type: EXPERIMENTAL
Intervention: Ketanserin, 40 mg b.i.d. for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30517252

Group type: EXPERIMENTAL
Intervention: 1,600 mg of oral magnesium hydroxide through nasogastric (NG) tube prior to surgery
Number of subjects: 82

Group type: COMPARATOR
Intervention: 2 g of magnesium sulfate during the induction of anesthesia
Number of subjects: 82
Study: 26423618

Group type: EXPERIMENTAL
Intervention: 3.6 mg pegteograstim
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 6.0 mg pegteograstim
Number of subjects: 117

Group type: COMPARATOR
Intervention: 6.0 mg pegfilgrastim
Number of subjects: 117
Study: 24560332

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Carboplatin/Vinorelbine (AUC5 and 25mg/m2 on days 1 and 8 every three weeks)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 284

Group type: COMPARATOR
Intervention: Carboplatin/Vinorelbine
Number of subjects: 284
Study: 22674719

Group type: COMPARATOR
Intervention: sulfaphenazole (cytochrome P450 inhibitor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: tetraethylammonium (TEA, KCa channel inhibitor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: l‐NAME (NO synthase inhibitor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: sulfaphenazole + l‐NAME
Number of subjects: 20

Group type: COMPARATOR
Intervention: l‐NAME + TEA
Number of subjects: 20

Group type: COMPARATOR
Intervention: TEA + l‐NAME
Number of subjects: 20
Study: 20570110

Group type: EXPERIMENTAL
Intervention: Amisulpride (200-1000 mg) plus Celecoxib (400 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Amisulpride (200-1000 mg) plus Placebo
Number of subjects: 49
Study: 17562798

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Number of subjects: 0
Study: 16055641

Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncertainty Salience (Control)
Number of subjects: 0
Study: 12205570

Group type: EXPERIMENTAL
Intervention: High-dose salmeterol (100 mcg, BID)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Albuterol (2.5 mg, BID)
Number of subjects: 44
Study: 10433674

Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver-coated dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mafenide acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 0
Study: 8543356

Group type: EXPERIMENTAL
Intervention: CPC-NaCl method
Number of subjects: 125

Group type: COMPARATOR
Intervention: NaOH method
Number of subjects: 125
Study: 2358610

Group type: EXPERIMENTAL
Intervention: Diltiazem (270 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18